

## DAFTAR PUSTAKA

1. Rodicio JL, Campo C, Ruilope LM. Microalbuminuria in essential hypertension. *Kidney Int* 2000;54(Suppl 68):S51-S4.
2. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. *Vasc Med* 2002;7:35-43.
3. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. *Am J Kidney Dis* 1999;34:996-1001.
4. Pontremoli R, Nicolella C, Viazzi F, *et al*. Microalbuminuria is an early marker of target organ damage in essential hypertension. *Am J Hypertens* 1998;11:430-8.
5. Caetano ER, Zatz R, Saldanha LB, *et al*. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. *Hypertension* 2001;38:171-6.
6. McLaughlin T, Reaven G. Insulin resistance and hypertension patient in double jeopardy for cardiovascular disease. *Geriatrics* 2000;55:28-35.
7. Klausen KP, Scharling H, Jensen G, *et al*. New definition of microalbuminuria in hypertensive subjects. *Hypertension* 2005;46:33-7.
8. Laasko M. Insulin resistance and coronary heart disease. *Curr Opin Lipidol* 1996;7:217-26.
9. Chen J, RP W, Hamm LL, *et al*. Association between inflammation and insulin resistance in U.S. non diabetic adult. *Diabetes Care* 2004;27(2960-2968).
10. Vanhala MJ, Pitkajarvi TK, Keinanen-Kiukaanniemi SM, *et al*. Hyperinsulinaemia in hypertensive subjects : validity of a test for the detection of insulin resistance in clinical practice. *J Hum Hypertension* 1998;12:463-7.
11. Ferrannini E, A N. Hypertension, insulin resistance and diabetes. In: Swales J, ed. *Textbook of Hypertension*. London: Blackwell Scientific Pub; 1994:785-97.
12. Sowers JR. Insulin resistance and hypertension. *Am J Physiol Heart Circ Physiol* 2004;286:H1597-H602.
13. Delbosc S, Critol JP, Descomps B, *et al*. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. *J Hypertens* 2002;40:142-7.
14. Julius S, Gudbrandsson T, Jamerson K, *et al*. The hemodynamic link between insulin resistance and hypertension. *J Hypertens* 1991;9:983-6.

15. Bakri S. Hipertensi pada obesitas. *Dalam* Obesitas dan Sindroma Metabolic. 1 ed. Bandung 2006.
16. Bianchi S, Bigazzi R, Galvan AQ, *et al.* Insulin resistance in microalbuminuric hypertension. *J Hypertens* 1995;26(789):1-15.
17. Redon J, Miralles A, Pascual JM, *et al.* Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. *J Hypertens* 1997;15:79-86.
18. Mykkanen L, Zaccaro DJ, Wagenknecht, *et al.* Microalbuminuria is associated with insulin resistance in nondiabetic subjects the insulin resistance atherosclerosis study. *Diabet Med* 1998;47:793-800.
19. Halimi JM, Forhan A, Balkau B, *et al.* Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women ?D.E.S.I.R. study group. *J Cardiovasc Risk* 2001;8:139-46.
20. Grandi AM, Santillo R, Zanzi P, *et al.* Microalbuminuria in never-treated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. *Am J Hypertens* 2000;13:353-8.
21. Bakris GL. Microalbuminuria : prognostic implications. *Curr Opin Nephrol Hypertens* 1996;5:219-23.
22. Remuzzi G BT. Pathophysiology of progressive nephropathies. *N Engl J Med*, 1998;20:1448-1456. 1998.
23. Klahr S. Prevention of progression of nephropathy. *Nephrol Dial Transplant* 1997;12(suppl2):63-6.
24. Ruilope LM, Rodicio JL. Hypertension, atherosclerosis and microalbuminuria in ELSA. *Blood Press* 1996;18:645-54.
25. Hirose H, Saito I, Kawabe H, *et al.* Insulin resistance and hypertension : seven-year follow-up study in middle-age Japanese men (the KEIO study). *Hypertens Res* 2003;26:795-800.
26. Juutilainen A, Lehto S, Ronnemaa T, *et al.* Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. *Diabetologia* 2006:56-65.
27. Steinberg HO. Insulin resistance and hypertension. In: Basic Science/Pathophysiology of Essential Hypertension. Philadelphia: WB Saunders Co; 1996:121-2.
28. Fagot-campagna A, Balkau B, Simon D, *et al.* Is insulin an independent factor for hypertension ? The Paris prospective study. *Int J Epidemiol* 1997;26:542- 50.

29. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. *Am Heart J* 1991;121:1274-82.
30. Mediratta S, Fozailoff A, Frishman WH. Insulin resistance in systemic hypertension : pharmacotherapeutic implications. *J Clin Pharmacol* 1995;35:943-56.
31. Toft I, Bonaa KH, Eikrem J, *et al*. Microalbuminuria in hypertension is not a determinant of insulin resistance. *Kidney Int* 2002;61:1445-52.
32. Chen J, Muntner P, Hamm LL, *et al*. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. *J Am Soc Nephrol* 2003;14:469-77.
33. Chobanian AV, Bakris GL, Black HR, *et al*. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, the JNC 7 Report. *JAMA* 2003;289:2560-72.
34. K/DOQI. Clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(suppl 1):S17-S31.
35. Perkeni 2002. Konsensus pengelolaan diabetes melitus di Indonesia.
36. Sukandar E. Infeksi (non spesifik dan spesifik) saluran kemih dan ginjal. *Dalam: Nefrologi Klinik*. 3 ed. Bandung: PII Bagian Penyakit Dalam Fakultas Kedokteran UNPAD; 2006:29-50.
37. Kubo M, Kiyohara Y, Kato I, *et al*. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. *Kidney Int* 1999;55:2450-6.

1. Rodicio JL, Campo C, Ruilope LM. Microalbuminuria in essential hypertension. *Kidney Int* 2000;54(Suppl 68):S51-S4.
2. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. *Vasc Med* 2002;7:35-43.
3. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. *Am J Kidney Dis* 1999;34:996-1001.
4. Pontremoli R, Nicolella C, Viazzi F, *et al*. Microalbuminuria is an early marker of target organ damage in essential hypertension. *Am J Hypertens* 1998;11:430-8.
5. Caetano ER, Zatz R, Saldanha LB, *et al*. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. *Hypertension* 2001;38:171-6.
6. McLaughlin T, Reaven G. Insulin resistance and hypertension patient in double jeopardy for cardiovascular disease. *Geriatrics* 2000;55:28-35.
7. Klausen KP, Scharling H, Jensen G, *et al*. New definition of microalbuminuria in hypertensive subjects. *Hypertension* 2005;46:33-7.
8. Laasko M. Insulin resistance and coronary heart disease. *Curr Opin Lipidol* 1996;7:217-26.
9. Chen J, RP W, Hamm LL, *et al*. Association between inflammation and insulin resistance in U.S. non diabetic adult. *Diabetes Care* 2004;27(2960-2968).
10. Vanhala MJ, Pitkajarvi TK, Keinanen-Kiukaanniemi SM, *et al*. Hyperinsulinaemia in hypertensive subjects : validity of a test for the detection of insulin resistance in clinical practice. *J Hum Hypertension* 1998;12:463-7.
11. Ferrannini E, A N. Hypertension, insulin resistance and diabetes. In: Swales J, ed. *Textbook of Hypertension*. London: Blackwell Scientific Pub; 1994:785-97.
12. Sowers JR. Insulin resistance and hypertension. *Am J Physiol Heart Circ Physiol* 2004;286:H1597-H602.
13. Delbosc S, Critol JP, Descomps B, *et al*. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. *J Hypertens* 2002;20:142-7.
14. Julius S, Gudbrandsson T, Jamerson K, *et al*. The hemodynamic link between insulin resistance and hypertension. *J Hypertens* 1991;9:983-6.

15. Bakri S. Hipertensi pada obesitas. *Dalam* Obesitas dan Sindroma Metabolic. 1 ed. Bandung 2006.
16. Bianchi S, Bigazzi R, Galvan AQ, *et al.* Insulin resistance in microalbuminuric hypertension. *J Hypertens* 1995;26(789):1-15.
17. Redon J, Miralles A, Pascual JM, *et al.* Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. *J Hypertens* 1997;15:79-86.
18. Mykkanen L, Zaccaro DJ, Wagenknecht, *et al.* Microalbuminuria is associated with insulin resistance in nondiabetic subjects the insulin resistance atherosclerosis study. *Diabet Med* 1998;47:793-800.
19. Halimi JM, Forhan A, Balkau B, *et al.* Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women ?D.E.S.I.R. study group. *J Cardiovasc Risk* 2001;8:139-46.
20. Grandi AM, Santillo R, Zanzi P, *et al.* Microalbuminuria in never-treated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. *Am J Hypertens* 2000;13:353-8.
21. Bakris GL. Microalbuminuria : prognostic implications. *Curr Opin Nephrol Hypertens* 1996;5:219-23.
22. Remuzzi G BT. Pathophysiology of progressive nephropathies. *N Engl J Med*, 1998;20:1448-1456. 1998.
23. Klahr S. Prevention of progression of nephropathy. *Nephrol Dial Transplant* 1997;12(suppl2):63-6.
24. Ruilope LM, Rodicio JL. Hypertension, atherosclerosis and microalbuminuria in ELSA. *Blood Press* 1996;18:645-54.
25. Hirose H, Saito I, Kawabe H, *et al.* Insulin resistance and hypertension : seven-year follow-up study in middle-age Japanese men (the KEIO study). *Hypertens Res* 2003;26:795-800.
26. Juutilainen A, Lehto S, Ronnemaa T, *et al.* Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. *Diabetologia* 2006:56-65.
27. Steinberg HO. Insulin resistance and hypertension. In: Basic Science/Pathophysiology of Essential Hypertension. Philadelphia: WB Saunders Co; 1996:121-2.
28. Fagot-campagna A, Balkau B, Simon D, *et al.* Is insulin an independent factor for hypertension ? The Paris prospective study. *Int J Epidemiol* 1997;26:542- 50.

29. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. *Am Heart J* 1991;121:1274-82.
30. Mediratta S, Fozailoff A, Frishman WH. Insulin resistance in systemic hypertension : pharmacotherapeutic implications. *J Clin Pharmacol* 1995;35:943-56.
31. Toft I, Bonaa KH, Eikrem J, *et al*. Microalbuminuria in hypertension is not a determinant of insulin resistance. *Kidney Int* 2002;61:1445-52.
32. Chen J, Muntner P, Hamm LL, *et al*. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. *J Am Soc Nephrol* 2003;14:469-77.
33. Chobanian AV, Bakris GL, Black HR, *et al*. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, the JNC 7 Report. *JAMA* 2003;289:2560-72.
34. K/DOQI. Clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(suppl 1):S17-S31.
35. Perkeni 2002. Konsensus pengelolaan diabetes melitus di Indonesia.
36. Sukandar E. Infeksi (non spesifik dan spesifik) saluran kemih dan ginjal. *Dalam: Nefrologi Klinik*. 3 ed. Bandung: PII Bagian Penyakit Dalam Fakultas Kedokteran UNPAD; 2006:29-50.
37. Kubo M, Kiyohara Y, Kato I, *et al*. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. *Kidney Int* 1999;55:2450-6.

## Lampiran 2

### PERNYATAAN PERSETUJUAN

Yang bertanda tangan dibawah ini :

Nama : .....

Umur : .....tahun

Alamat : .....

Pekerjaan : .....

Dengan ini bersedia mengikuti penelitian “nilai *Homeostatic Model Assessment-Insulin Resistance (HOMA-IR)* pada penderita hipertensi dengan mikroalbuminuria” setelah mendengarkan penjelasan dan manfaatnya bagi perkembangan Ilmu Kedokteran.

Makassar, - - 2006

Peneliti

Yang membuat pernyataan,

( dr. Hasan )

( \_\_\_\_\_ )

## Lampiran 1

### FOMULIR PENELITIAN

RS/No. Rekam Medis : (LB/WS)/ Alamat : \_\_\_\_\_

Nama : \_\_\_\_\_ No. Telepon : \_\_\_\_\_

Umur : \_\_\_\_\_ Tgl Pemeriksaan : \_\_\_\_\_

Pekerjaan : \_\_\_\_\_

#### I. ANAMNESIS:

1. Keluhan : \_\_\_\_\_

2. Riwayat penyakit sebelumnya : \_\_\_\_\_

3. Riwayat penyakit dalam keluarga : \_\_\_\_\_

    Diabetes melitus : Tidak / ya, siapa \_\_\_\_\_

    Hipertensi : Tidak/ ya, siapa \_\_\_\_\_

4. Riwayat terakhir minum obat antihipertensi : \_\_\_\_ mgg, Jenis : \_\_\_\_\_

#### II. PEMERIKSAAN FISIS :

1. Tinggi Badan : \_\_\_\_ cm Lingkar Perut : \_\_\_\_cm Berat Badan : \_\_\_\_kg

2. Tanda Vital: Tekanan Darah (TD) I : \_\_\_\_/ \_\_\_\_ mmHg, TD II : \_\_\_\_/ \_\_\_\_ mmHg

    Nadi : \_\_\_\_ x /mnt, Pernapasan : \_\_\_\_ x / menit, Suhu : \_\_\_\_ °C

3. Kepala : \_\_\_\_\_

4. Leher : \_\_\_\_\_

5. Paru-paru : \_\_\_\_\_

6. Jantung : \_\_\_\_\_

7. Abdomen : \_\_\_\_\_

8. Ekstremitas edem : ya / tidak

#### III. PEMERIKSAAN LABORATORIUM :

- Urinalisis lekosit  $\geq$  10.000/lpb: ya / tidak      Kreatinin darah : \_\_\_\_ mg/dl

- Kadar albumin urin : \_\_\_\_  $\mu$ g/dl      Tgl, - - 2006

- Kadar kreatinin urin : \_\_\_\_  $\mu$ g/dl

- Gula darah puasa : \_\_\_\_ mg/dl

- Kadar insulin darah puasa : \_\_\_\_  $\mu$ g/dl (\_\_\_\_)